業績公告
即時報告
8-K
2026-07-13
Alto Neuroscience提交8-K 初步估算現金約2.44億美元 加速ALTO-207第三期臨床開發
AI 繁中摘要
Alto Neuroscience（NYSE: ANRO）於2026年7月13日提交8-K表格，披露最新財務狀況及臨床開發計劃。截至2026年6月30日，公司初步估算現金、現金等價物及受限制現金約為2.442億美元（未經審計），數字或於完成第二季度會計程序後調整，可能出現重大差異。💰
管理層同時宣佈，將加速並擴大其最先進項目ALTO-207的臨床開發，包括計劃新增一項針對治療抵抗性抑鬱症的單藥療法第三期試驗。此舉顯示公司戰略上進一步聚焦該候選藥物，期望加快推進至後期階段。
對投資者而言，充裕的現金儲備（約2.44億美元）為ALTO-207的擴展臨床計劃提供即時資金支持，有助降低短期融資壓力。然而，上述數字屬初步估算，投資者須留意最終經審計結果可能帶來的波動。此外，管線加速雖帶來潛在催化劑，但新第三期試驗存在臨床失敗、監管延誤等風險，相關不確定因素已在公司10-K年報及後續SEC文件中詳述。
公司重申，前瞻性陳述（包括臨床開發時間表）僅截至報告日期，不負有更新責任。
展開英文正文
false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2026 ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-41944 83-4210124 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 650 Castro Street, Suite 450, Mountain View, CA 94041 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ANRO New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 2.02.Results of Operations and Financial Condition. The information disclosed under the heading “Cash, Cash Equivalents and Restricted Cash as of June 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01Other Events. Cash, Cash Equivalents and Restricted Cash as of June 30, 2026 On July 13, 2026, Alto Neuroscience, Inc. (the “Company”) announced that, based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and restricted cash as of June 30, 2026 may differ from these amounts after it completes its comprehensive accounting procedures for the quarter ended June 30, 2026, and any such differences may be material. Pipeline Update The Company intends to accelerate and expand the clinical development of its most advanced program, ALTO-207, including to conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Company’s clinical development plans for ALTO-207, and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that the Company may make with the SEC, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: July 13, 2026 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer